Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line. The aim of this analysis is to evaluate the benefit of ICI across different treatment lines.

Patients and methods

This is a single-center retrospective study that included mRCC patients who received ICIs in various treatment lines. Objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) were evaluated.

Results

Ninety-four patients were eligible for full evaluation. Patients were classified as International mRCC Database Consortium (IMDC) risk group categorization as good, intermediate and poor risk in 26.8%, 61.6% and 14.8

SUBMITTER: Resch I 

PROVIDER: S-EPMC8261552 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature